Actuate Therapeutics
ACTU
45 hedge funds and large institutions have $80.2M invested in Actuate Therapeutics in 2025 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 22 increasing their positions, 8 reducing their positions, and 6 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 8
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
4.66% more ownership
Funds ownership: 51.74% → 56.4% (+4.7%)
5% more funds holding
Funds holding: 43 → 45 (+2)
0% less capital invested
Capital invested by funds: $80.5M → $80.2M (-$221K)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Voss Capital
Houston,
Texas
|
+$2.77M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.46M |
| 3 |
BlackRock
New York
|
+$1.03M |
| 4 |
TCBWMS
Texas Capital Bank Wealth Management Services
Dallas,
Texas
|
+$650K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$428K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCH
Freestone Capital Holdings
Seattle,
Washington
|
-$66.9K |
| 2 |
NU
Northwestern University
Evanston,
Illinois
|
-$43.4K |
| 3 |
WANY
Wealthspire Advisors (New York)
New York
|
-$33.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$26.1K |
| 5 |
LPL Financial
San Diego,
California
|
-$22.3K |
ACTU Hedge Fund Activity: Q4 2025 in Review
45 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Actuate Therapeutics (ACTU) for Q4 2025, worth a combined $80.2M — down 0.28% from $80.5M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ACTU positions and 6 closed out — a net gain of 2 holders — while 22 added to existing stakes and 8 trimmed.
The largest buyer was Voss Capital, adding an estimated $2.77M. The largest seller was Freestone Capital Holdings, exiting entirely with an estimated $66.9K sold.
- 45 institutional investors held Actuate Therapeutics (ACTU) as of Q4 2025, up from 43 in Q3 2025.
- Funds reported $80.2M of Actuate Therapeutics stock for Q4 2025, down 0.28% quarter-over-quarter.
- 8 funds opened new Actuate Therapeutics positions in Q4 2025 and 6 closed out, a net change of +2 holders.
- The largest Actuate Therapeutics buyer in Q4 2025 was Voss Capital, an estimated $2.77M added.
- The largest Actuate Therapeutics seller in Q4 2025 was Freestone Capital Holdings, an estimated $66.9K sold.
Based on aggregated 13F filings for Q4 2025.